Pharmacopeia

CWP-0161

Methylene blue

Antidotes · Level 3

Core pharmacology

Class Group

Thiazine dye; oxidation-reduction agent and methaemoglobinaemia antidote.

Main Action

Promotes reduction of methaemoglobin (Fe3+) to functional haemoglobin (Fe2+); in vasoplegia, inhibits nitric-oxide/cGMP-mediated vasodilatation (off-label use).

Mechanism of action

NADPH-dependent reduction converts methylene blue to leucomethylene blue, which donates reducing equivalents to methaemoglobin. In vasoplegia, inhibitory effects on nitric oxide synthase/soluble guanylate cyclase can decrease cGMP signalling.

Indications Uses

Treatment of acquired methaemoglobinaemia; a rescue therapy sometimes considered for refractory vasoplegia, which is a separate off-label indication with less certain outcome evidence.

Route And Dose

Intravenous for clinically significant acquired methaemoglobinaemia; follow locally approved product information and toxicology advice for dose, repeat dosing and preparation. Do not extrapolate a methaemoglobinaemia regimen to vasoplegia.

Metabolism

Reduced in tissues to leucomethylene blue; redox cycling mediates methaemoglobin reduction.

Adverse Effects Toxicity

Potentially severe serotonin syndrome with serotonergic medicines and some opioids due to MAO-inhibiting activity; haemolysis and reduced effectiveness in G6PD deficiency; paradoxical methaemoglobinaemia with excessive doses; blue-green discolouration and interference with pulse oximetry.

Special Points

US methylene blue injection labelling contraindicates use in G6PD deficiency and contains a boxed serotonin-syndrome warning. In acquired methaemoglobinaemia, monitor clinical response and co-oximetry rather than relying on pulse oximetry alone. Vasoplegic-shock use remains off-label and should not be presented as equivalent to the established antidote indication.

Source references

These October 2026 additions were reconciled against the linked sources. Refer to current local formulary guidance for clinical prescribing.